BioInvent International has announced that it has been granted a US patent for its antibody and concomitant target discovery technology F.I.R.S.T.
The F.I.R.S.T. technology is a novel discovery method which allows for antibodies and disease targets to be identified simultaneously. BioInvent has used the technology successfully in several proprietary discovery projects and and offers F.I.R.S.T. as well as traditional antibody discovery screening to commercial partners.
“With billions of binders available in the libraries and state-of-the-art in vitro and in vivo cancer and immunological assays, we can discover antibodies with the very best properties for onward development.” Said Björn Frendeus, VP Preclinical Research at BioInvent.